Home | Complete Product Information | Print This Page | Site Map
Search
blue bar
Pandemic Planning Toolkit A resource to assist your organization in preparing for pandemic influenza

TAMIFLU® (oseltamivir phosphate) has been studied only in strains of influenza that were circulating at the time. The magnitude of effect of TAMIFLU in treating and preventing novel strains of influenza, such as those that may be involved in a pandemic, cannot be predicted.

 
Step Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7
 
Store antivirals for your organization

It is important to consider where and how your organization will store the supply of TAMIFLU it receives. TAMIFLU capsules are supplied in blister packages of 10 (NDC 0004-0800-85). They are 75 mg grey/light yellow hard gelatin capsules. "Roche" is printed in blue ink on the grey body, and "75 mg" is printed in blue ink on the light yellow cap. The following checklist will help you to select a suitable storage site.

 

 Storage Blister Pack Calculator  
Number of TAMIFLU blister packs:
 Approximate numbers of cases: 0
Approximate numbers of pallets:
0
Approximate storage space required (sq. ft.):
0
   

How Supplied

  • Each case contains 88 blisters.
  • Each pallet contains either 45 or 56 cases depending on configuration.
  • The dimensions and weight case and pallet are as follows:

Case Configuration
  • Number of blister packs per case = 88
  • Length, width, depth
    • Configuration 1: 13.375"L x 10.125"W x 8.625"H
    • Configuration 2: 13.438"L x 8.875"W x 10.562"H
Pallet Configuration
  • Number of cases per pallet = 45 or 56
  • Length and width
    • 40.5" x 48" = 56 cases
    • 42" x 48" = 45 cases

     

    red checkmark  Understand criteria for TAMIFLU storage
    An organization can store product at any entity that meets ALL of the following criteria:
    • Adheres to TAMIFLU product storage requirements (see Package Insert)
    • Adheres to storage guidelines of United States Pharmacopeia (USP) www.usp.org
    • Has sufficient and appropriate storage based on order quantity and distribution plan
    The entity must also meet these TAMIFLU storage requirements:
    • TAMIFLU capsules must be stored at 25º Celsius (77º Fahrenheit); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF).
     
    red checkmark  Identify and contact entities and evaluate their capacity to store TAMIFLU for your organization
    In most cases, an organization can store product at any of the following locations:
    • Company warehouse or storage facility in compliance with the aforementioned criteria
    • Pharmaceutical wholesaler
    • Specialty distributor
    • Pharmacy Benefit Manager
    • Company or community clinic
    • Physician's office
    Notes:
    - Other options may exist
    - Not all companies will be able to store product

     
    Step Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7
     

     
    Guidelines
    Download Guidelines

    CDC Guidelines WHO Guidelines OSHA Guidelines
    Contact Us Contact Us
    Indications and Important Safety Information

     

    Indications

    TAMIFLU is indicated for the treatment of uncomplicated influenza caused by viruses types A and B in patients 1 year and older who have been symptomatic for no more than 2 days.

    TAMIFLU is also indicated for the prophylaxis of influenza in patients 1 year and older.

    TAMIFLU is not a substitute for early and annual vaccination as recommended by the Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP).

    Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use TAMIFLU.

    Safety Information

    There is no evidence for efficacy against any illness caused by agents other than influenza types A and B.

    Treatment efficacy in subjects with chronic cardiac and/or respiratory disease has not been established. No difference in the incidence of complications was observed between the treatment and placebo groups in this population.

    No information is available regarding treatment of influenza in patients at imminent risk of requiring hospitalization.

    Efficacy of TAMIFLU has not been established in immunocompromised patients.

    Safety and efficacy of repeated treatment or prophylaxis courses have not been studied.

    Influenza can be associated with a variety of neurologic and behavioral symptoms, which can include events such as hallucinations, delirium and abnormal behavior, in some cases resulting in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can occur without obvious severe disease. There have been postmarketing reports (mostly from Japan) of delirium and abnormal behavior leading to injury, and in some cases resulting in fatal outcomes, in patients with influenza who were receiving TAMIFLU. Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made but they appear to be uncommon based on TAMIFLU usage data. These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution. The contribution of TAMIFLU to these events has not been established. Patients with influenza should be closely monitored for signs of abnormal behavior. If neuropsychiatric symptoms occur, the risks and benefits of continuing treatment should be evaluated for each patient.

    In postmarketing experience, rare cases of anaphylaxis and serious skin reactions, including toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme, have been reported with TAMIFLU.

    The most common adverse events reported >1% of patients treated with TAMIFLU and more commonly than in patients treated with placebo are:

    • Treatment of adult and pediatric patients - nausea, vomiting.
    • Prophylaxis of adult and pediatric patients - nausea, vomiting, abdominal pain.

    Vaccination is considered the first line of defense against influenza.

    Please see TAMIFLU full Prescribing Information for additional safety information.

     

    Roche